JDD Buzz Series | Concerns & Diagnoses Among Patients with Skin of Color
People with skin of color are projected to become the majority of the U.S. population by 2044. As the population diversifies, how can dermatology clinicians better understand the dermatologic concerns of people with darker skin tones? A study published in the April Journal of Drugs in Dermatology sheds light on the most common reasons why patients of color seek outpatient dermatologic care, and th …
People with skin of color are projected to become the majority of the U.S. population by 2044. As the population diversifies, how can dermatology clinicians better understand the dermatologic concerns of people with darker skin tones? A study published in the April Journal of Drugs in Dermatology sheds light on the most common reasons why patients of color seek outpatient dermatologic care, and th … Continue reading "JDD Buzz Series | Concerns & Diagnoses Among Patients with Skin of Color"
In today’s digital media landscape, dermatologists are increasingly called upon to serve as trusted voices in the public conversation around skin health, beauty trends, and medical misinformation. For dermatology experts early in their career or seasoned dermatologists looking to enter the digital space, navigating the media can feel daunting. However, with the right approach, it becomes a valua … 
The FDA’s alert on the safety of topical finasteride is one of the dermatology news stories making headlines in the consumer press. New Beauty interviewed three dermatologists for their perspective on the popular hair loss treatment. Dermatologist Dr. Skylar Souyoul notes that topical finasteride does not have the same level of clinical study as oral finasteride. Dr. Natanel Jourabchi says it’ … 
A 35-year-old female presents to dermatology clinic for the pictured rash, which has been recurring at least once per week for the past six months. Which of the following treatment options works by reducing mast cell degranulation through Bruton tyrosine kinase inhibition?
A. Dupilumab
B. Benralizumab
C. Cromolyn sodium
D. … 
Sexually transmitted diseases are at a crisis state in patients with skin of color. That’s according to Dr. Theodore Rosen, professor of dermatology at Baylor College of Medicine and chief of dermatology service at Michael DeBakey Veterans Affairs Medical Center. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Rosen, who shared about three diseases that are at sweep …